Charles Swanton

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. pmc Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
    Dean A Fennell
    University of Leicester and Leicester University Hospitals, Hodgkin Building, Lancaster Road, PO Box 138, Leicester, LE1 9HN, UK
    EPMA J 3:6. 2012
  2. pmc Intratumor heterogeneity: evolution through space and time
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Cancer Res 72:4875-82. 2012
  3. doi From genomic landscapes to personalized cancer management-is there a roadmap?
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Ann N Y Acad Sci 1210:34-44. 2010
  4. ncbi Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs
    Charles Swanton
    Signal Transduction Laboratory, Cancer Research UK London Research Institute, London, UK
    Cell Cycle 6:2001-4. 2007
  5. pmc Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer
    Hilda Wong
    Division of Hematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Oncologist 16:1535-46. 2011
  6. pmc Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, UK
    Breast Cancer Res 10:214. 2008
  7. ncbi Chromosomal instability, colorectal cancer and taxane resistance
    Charles Swanton
    Royal Marsden Hospital, Department of Medicine, London, UK
    Cell Cycle 5:818-23. 2006
  8. pmc Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
    Charles Swanton
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London, WC2A 3PX, UK
    Genome Med 2:53. 2010
  9. pmc Breast cancer genome heterogeneity: a challenge to personalised medicine?
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Breast Cancer Res 13:104. 2011
  10. doi Parallel evolution of tumour subclones mimics diversity between tumours
    Pierre Martinez
    Cancer Research UK London Research Institute, London, UK
    J Pathol 230:356-64. 2013

Detail Information

Publications49

  1. pmc Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
    Dean A Fennell
    University of Leicester and Leicester University Hospitals, Hodgkin Building, Lancaster Road, PO Box 138, Leicester, LE1 9HN, UK
    EPMA J 3:6. 2012
    ....
  2. pmc Intratumor heterogeneity: evolution through space and time
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Cancer Res 72:4875-82. 2012
    ....
  3. doi From genomic landscapes to personalized cancer management-is there a roadmap?
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Ann N Y Acad Sci 1210:34-44. 2010
    ..We argue that the failure to adopt these methods rapidly into clinical trial design will increase late stage drug attrition, waste trial resources, and risk patient harm within unselected cohorts...
  4. ncbi Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs
    Charles Swanton
    Signal Transduction Laboratory, Cancer Research UK London Research Institute, London, UK
    Cell Cycle 6:2001-4. 2007
    ..Furthermore, this work supports efforts to identify common pathways of drug response for future drug discovery programmes...
  5. pmc Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer
    Hilda Wong
    Division of Hematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Oncologist 16:1535-46. 2011
    ..The identification of predictive biomarkers is of paramount importance to optimize health economic costs and enhance stratification of anti-HER-2 targeted therapies...
  6. pmc Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, UK
    Breast Cancer Res 10:214. 2008
    ....
  7. ncbi Chromosomal instability, colorectal cancer and taxane resistance
    Charles Swanton
    Royal Marsden Hospital, Department of Medicine, London, UK
    Cell Cycle 5:818-23. 2006
    ..A phase II trial of taxanes in patients with metastatic CIN negative CRC may be indicated...
  8. pmc Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
    Charles Swanton
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London, WC2A 3PX, UK
    Genome Med 2:53. 2010
    ....
  9. pmc Breast cancer genome heterogeneity: a challenge to personalised medicine?
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Breast Cancer Res 13:104. 2011
    ....
  10. doi Parallel evolution of tumour subclones mimics diversity between tumours
    Pierre Martinez
    Cancer Research UK London Research Institute, London, UK
    J Pathol 230:356-64. 2013
    ....
  11. doi CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction
    Alvin J X Lee
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    J Pathol 226:482-94. 2012
    ....
  12. ncbi Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs
    Charles Swanton
    Signal Transduction, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Cancer Cell 11:498-512. 2007
    ..COL4A3BP expression is increased in drug-resistant cell lines and in residual tumor following paclitaxel treatment of ovarian cancer, suggesting that it could be a target for chemotherapy-resistant cancers...
  13. doi Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges
    Stuart Horswell
    Cancer Research UK London Research Institute, London, UK Electronic address
    Cancer Lett 340:220-6. 2013
    ....
  14. pmc Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target
    Marco Gerlinger
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, Lincoln s Inn Fields, London, WC2A 3LY, UK
    J Pathol 227:146-56. 2012
    ..These data suggest that MCT4 may serve as a novel metabolic target to reverse the Warburg effect and limit disease progression in ccRCC...
  15. doi Replication stress links structural and numerical cancer chromosomal instability
    REBECCA A BURRELL
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Nature 494:492-6. 2013
    ..These data implicate a central role for replication stress in the generation of structural and numerical CIN, which may inform new therapeutic approaches to limit intratumour heterogeneity...
  16. pmc Chromosomal instability determines taxane response
    Charles Swanton
    Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom
    Proc Natl Acad Sci U S A 106:8671-6. 2009
    ..Thus, pretherapeutic assessment of CIN may optimize treatment stratification and clinical trial design using these agents...
  17. doi Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer
    REBECCA A BURRELL
    Translational Cancer Therapeutics Laboratory, London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    J Cell Biochem 111:782-90. 2010
    ..A greater understanding of karyotypic complexity and identification of methods to directly examine and target CIN may support novel strategies to improve outcome in cancer...
  18. doi Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
    Marco Gerlinger
    Cancer Research UK London Research Institute, London, United Kingdom
    N Engl J Med 366:883-92. 2012
    ..Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples...
  19. ncbi Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy
    Sarah E McClelland
    Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London, UK
    Cell Cycle 8:3262-6. 2009
    ....
  20. doi Implications of intratumour heterogeneity for treatment stratification
    Andrew Crockford
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, WC2A 3LY, UK
    J Pathol 232:264-73. 2014
    ..We also discuss the predictive potential of patient-derived models of tumour response, including xenograft and cell line-based systems within the context of intratumour heterogeneity...
  21. pmc A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables
    David Endesfelder
    Cancer Research UK London Research Institute, London, WC2A 3LY, United Kingdom
    Oncotarget 2:529-37. 2011
    ..These data support the hypothesis that chromosomal instability may be a defining feature of breast cancer biology and clinical outcome...
  22. pmc Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer
    Rebecca Roylance
    Cancer Research UK, London Research Institute, London, United Kingdom
    Cancer Epidemiol Biomarkers Prev 20:2183-94. 2011
    ....
  23. pmc Chromosomal instability confers intrinsic multidrug resistance
    Alvin J X Lee
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Cancer Res 71:1858-70. 2011
    ..Our results suggest that stratifying tumor responses according to CIN status should be considered within the context of clinical trials to minimize the confounding effects of tumor CIN status on drug sensitivity...
  24. pmc Cancer chromosomal instability: therapeutic and diagnostic challenges
    Nicholas McGranahan
    Translational Cancer Therapeutics Laboratory, CRUK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    EMBO Rep 13:528-38. 2012
    ..The relationship between CIN and prognosis supports assessment of CIN status in the clinical setting and suggests that stratifying tumours according to levels of CIN could facilitate clinical risk assessment...
  25. doi Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics
    Alvin J X Lee
    Translational Cancer Therapeutics, Cancer Research UK London Research Institute, UK
    Biochem Pharmacol 83:1013-20. 2012
    ....
  26. doi Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference
    Daniel S W Tan
    Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom
    Eur J Cancer 46:2166-77. 2010
    ..This represents a rational approach to accelerate biomarker discovery, maximising the potential for therapeutic benefit and minimising the health economic cost of ineffective therapy...
  27. doi Genetic prognostic and predictive markers in colorectal cancer
    Axel Walther
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK
    Nat Rev Cancer 9:489-99. 2009
    ..In this Review, we attempt to summarize the sometimes confusing findings, and critically assess those markers already in the public domain...
  28. doi The causes and consequences of genetic heterogeneity in cancer evolution
    REBECCA A BURRELL
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Nature 501:338-45. 2013
    ..By understanding these mechanisms we can gain insight into the common pathways of tumour evolution that could support the development of future therapeutic strategies. ..
  29. doi Intratumor heterogeneity: seeing the wood for the trees
    Timothy A Yap
    Department of Medicine, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Sci Transl Med 4:127ps10. 2012
    ..Envisaging tumor growth as a Darwinian tree with the trunk representing ubiquitous mutations and the branches representing heterogeneous mutations may help in drug discovery and the development of predictive biomarkers of drug response...
  30. doi Unraveling the complexity of endocrine resistance in breast cancer by functional genomics
    Charles Swanton
    Cancer Research UK London Research Institute, Signal Transduction Laboratory, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Cancer Cell 13:83-5. 2008
    ..CDK10 is thus a potential biomarker for sensitivity in prospective clinical trials of patients treated with endocrine therapies...
  31. ncbi RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?
    Charles Swanton
    Signal Transduction Laboratory, Cancer Research UK London Research Institute, London, UK
    Lancet Oncol 5:653-4. 2004
  32. doi Computational optimisation of targeted DNA sequencing for cancer detection
    Pierre Martinez
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Sci Rep 3:3309. 2013
    ..Our analyses demonstrate that targeting "hotspot" regions would introduce biases towards in-frame mutations and would compromise the reproducibility of tumour detection. ..
  33. pmc LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development
    Liwen Lu
    Lungs for Living Research Centre, UCL Respiratory, University College London, 5 University Street, London, WC1E 6JF, UK
    J Pathol 229:608-20. 2013
    ..Our findings imply that the early stages of squamous carcinoma development are driven by a change in amplitude of EGFR signalling governed by the loss of contact inhibition...
  34. doi Response to bakhoum et Al
    REBECCA A BURRELL
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Curr Biol 24:R150. 2014
    ..We therefore favour the broader definition of CIN as "losses and gains of whole chromosomes or large portions thereof" as described by the Vogelstein laboratory [6] and commonly used by others. ..
  35. doi Adapting clinical paradigms to the challenges of cancer clonal evolution
    Nirupa Murugaesu
    University College London Cancer Institute, London, United Kingdom
    Am J Pathol 182:1962-71. 2013
    ....
  36. doi Epigenetic regulation in RCC: opportunities for therapeutic intervention?
    James Larkin
    Department of Medicine, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Nat Rev Urol 9:147-55. 2012
    ..An improved understanding of histone and chromatin regulation in RCC biology and the consequences of intratumor heterogeneity might identify novel targets in RCC and present alternative therapeutic opportunities...
  37. doi Recent developments in treatment stratification for metastatic breast cancer
    Sarah Barton
    Breast Unit, Royal Marsden Hospital, London and Sutton, UK
    Drugs 71:2099-113. 2011
    ..The future management of MBC will increasingly focus on stratifying therapeutics based on individualized-tumour molecular aberrations...
  38. doi RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance
    Alvin J X Lee
    Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London, UK
    Expert Rev Mol Med 11:e15. 2009
    ..The challenge is how to integrate these data with biological samples to define relevant drug-resistant pathways in vivo...
  39. ncbi Her2-targeted therapies in non-small cell lung cancer
    Charles Swanton
    Cancer Research UK London Research Institute, Signal Transduction Laboratory, UK
    Clin Cancer Res 12:4377s-4383s. 2006
    ..The most promising Her2-targeted strategy will likely prove to be combinatorial approaches using an EGFR tyrosine kinase inhibitor together with Her2 dimerization inhibitors...
  40. doi Tumour heterogeneity and immune-modulation
    Mariam Jamal-Hanjani
    Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London WC2A 3LY, UK
    Curr Opin Pharmacol 13:497-503. 2013
    ....
  41. ncbi Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
    Thomas Yau
    Breast Unit, Royal Marsden Hospital, Surrey SM2 5PT, UK
    Acta Oncol 45:196-201. 2006
    ..This study shows brain metastases are common phenomenon in HER2 positive advanced breast cancer patients receiving trastuzumab and also may implicate the brain as a sanctuary site for early relapse in this patient cohort...
  42. ncbi New Targets and Innovative Strategies in Cancer Treatment: one year of progress. 13-14 February 2004, Nice, France
    Charles Swanton
    Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    IDrugs 7:306-11. 2004
  43. ncbi Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies
    Sarah Barton
    Royal Marsden Hospital, Department of Medicine, Breast Unit, Downs Road, Sutton, SM2 5PT, UK
    Curr Cancer Drug Targets 10:799-812. 2010
    ..Functional genomics elucidation of drug resistance pathways using RNA interference (RNAi) techniques may provide novel therapeutic approaches in disease resistant to EGFR pathway targeting and accelerate predictive biomarker development...
  44. pmc Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity
    Rosalie Fisher
    Cancer Research UK London Research Institute, Translational Cancer Therapeutics Laboratory, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    EPMA J 3:1. 2011
    ....
  45. doi A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK
    J Pathol 227:29-41. 2012
    ....
  46. ncbi Cell-cycle targeted therapies
    Charles Swanton
    Royal Marsden Hospital Breast Unit, Royal Marsden Hospital NHS Trust, London, UK
    Lancet Oncol 5:27-36. 2004
    ..This review will introduce the protein families that regulate the cell cycle, their aberrations in malignant progression and pharmacological strategies targeting this important process...
  47. doi Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action
    James Larkin
    Renal Cancer Unit, Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK
    Expert Rev Anticancer Ther 11:639-49. 2011
    ..Ongoing research will further define the relative merits of other sequences in terms of clinical outcome...
  48. pmc The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel
    Ahmed Ashour Ahmed
    Functional Genomics of Drug Resistance Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Cancer Cell 12:514-27. 2007
    ..These data show that ECM can mediate taxane sensitivity by modulating microtubule stability...
  49. ncbi Epothilones and new analogues of the microtubule modulators in taxane-resistant disease
    Michelle Harrison
    Royal Prince Alfred Hospital, Department of Medical Oncology, Missenden Road, Camperdown, Sydney 2050, Australia
    Expert Opin Investig Drugs 17:523-46. 2008
    ..Microtubule-stabilising agents typified by the epothilone class of drug have demonstrated promising activity in Phase II and III clinical trials...